Immune thrombocytopenic purpura caused by immune checkpoint inhibitors for uveal malignant melanoma
The Journal of Dermatology · 2023
DOI: 10.1111/1346-8138.16800 ↗Kurz gefasst
Leserbrief in der Zeitschrift The Journal of Dermatology, 2023. Verfasst von Keita Takemoto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Melanoma, Uveal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 3 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
ORCID-Profile: Keita Takemoto, Teruhiko Makino, Ko Kagoyama, Fumina Furukawa, Megumi Mizawa
Zitieren
APA
Takemoto, K., Makino, T., Kagoyama, K., Furukawa, F., Mizawa, M., & Shimizu, T. (2023). Immune thrombocytopenic purpura caused by immune checkpoint inhibitors for uveal malignant melanoma. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.16800
Vancouver
Takemoto K, Makino T, Kagoyama K, Furukawa F, Mizawa M, Shimizu T. Immune thrombocytopenic purpura caused by immune checkpoint inhibitors for uveal malignant melanoma. The Journal of Dermatology. 2023. doi:10.1111/1346-8138.16800
BibTeX
@article{Takemoto2023,
author = {Takemoto, Keita and Makino, Teruhiko and Kagoyama, Ko and Furukawa, Fumina and Mizawa, Megumi and Shimizu, Tadamichi},
title = {Immune thrombocytopenic purpura caused by immune checkpoint inhibitors for uveal malignant melanoma},
journal = {The Journal of Dermatology},
year = {2023},
doi = {10.1111/1346-8138.16800}
}
EUVIMED